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“The most difficult thing is to know what we do know, and what we do not 
know” 
 
Tertium Organum, 1920, P. D. Ouspensky 
 
 
 

  
ABSTRACT 
 
Metastatic spread of cancer cells to vital organs is the predominant cause of death among 
women suffering from breast and ovarian cancer, and invasive cancer cells are in many cases 
resilient to standard drugs used in the clinic. Consequently, further understanding of the 
metastatic process and development of new strategies to target invasive cancer cells are 
needed. One process that has been closely linked to cancer cell invasion and migration is 
epithelial-mesenchymal transition (EMT), a developmental process, which can be reactivated 
during cancer progression. EMT allows carcinoma cells, with an epithelial origin, to acquire 
mesenchymal and migratory properties that are employed to invade the surrounding tumor 
tissue. The overall aim of this thesis was to investigate how EMT is induced in breast and 
ovarian cancer cells and to study the role of EMT in drug resistance.  
 Relapse of resilient cancer cells after surgery and first line of drug treatments is 
a major cause of death in ovarian and breast cancer. Currently, little is known about the 
functional properties of cancer cells that develop resistance to existing drug treatments and 
how they can be targeted. The aim of study I was to characterize the phenotypic properties of 
ovarian cancer cells that developed resistance to cisplatin, a chemotherapeutic drug 
commonly used in the clinic. We found that human SKOV-3 ovarian cancer cells that 
acquired resistance to cisplatin gained properties of EMT and cancer stem cells, suggesting 
that they were more invasive than drug-sensitive cells. Indeed, functional experiments 
showed that cisplatin-resistant SKOV-3 cells were more migratory in invasion assays and 
displayed an increased tumor initiating capacity compared to cisplatin-sensitive cells. The 
results from these studies link EMT to drug resistance in ovarian cancer cells, and emphasize 
that further understanding of EMT is needed and to be able to target EMT for therapy.  
In study II-IV we investigated how cellular sensitivity to EMT is regulated. In 
particular, we focused on identifiying epithelial differentiation factors that regulate EMT in 
breast cancer cells. We identified two transcription factors – C/EBPβ and Foxp4 that were 
lost during breast cancer progression, which conferred cells an enhanced capacity to undergo 
EMT as well as to gain invasive and metastatic properties in experimental in vitro and in vivo 
models of breast cancer. In addition, we identified the coxsackie- and adenovirus receptor 
(CAR), a tight junction-based cell adhesion molecule, as a novel regulator of Akt signaling 
and TGF-β-induced EMT in breast cancer cells. The mechanism was traced to a role of CAR 
in regulating localization, stability and function of the phosphatase Pten, a potent Akt 
inhibitor, at tight junctions. The results from these studies indicate that the EMT process is 
not solely regulated by factors that drive a mesenchymal differentiation program, but also, is 
under tight control by epithelial differentiation factors. Loss of C/EBPβ, Foxp4 and CAR 
may lead to increased cellular sensitivity to EMT and thereby open up the possibility that 
cancer cells acquire invasive and migratory properties. Based on this, we propose that novel 
therapies aiming to strengthen, or preserve, epithelial differentiation mechanisms in breast or 
ovarian cancer cells, might be useful as a type of differentiation therapy to inhibit cancer cell 
invasion and metastasis.  
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I   INTRODUCTION 
 
1.1 Women´s Cancer  
 
Development of the human embryo, from one initial germ cell to a functional multi-cellular 
organism, is dependent on predetermined events of cellular transitions. In a controlled 
fashion, stem cells divide and differentiate into a number of different cell types, with the 
capacity to build up and maintain the physical functions of our body. This is made possible 
when cells follow proper genetic programs, which coordinate the course of development and 
the cellular response to external conditions.1,2 Cancer cells no longer follow proper genetic 
programs, and lose their ability to act in accordance with needs of the multi-cellular 
organism. In later stage of the cancerous disease, the potent force of transition is once more 
triggered and tumor cells not only divide rapidly, but change their morphology and turn 
invasive.3,4,5 
Women´s cancer comprises of malignancies of the cervical, ovarian, and breast 
epithelia and in more rare cases the vaginal and vulvar epithelia.6 The incident of death of 
cervical cancer patients has largely been reduced in several countries due to successful 
screening programs. In addition, vaccine against oncogenic human papilloma virus is likely 
to further reduce the incidence and death caused by cervical cancer.7 However for breast 
cancer, the most common malignant disease among women in the western world, and ovarian 
cancer breakthroughs in finding new therapeutic alternatives are well needed.8,9 In particular, 
it would be of interest to identify and be able to target the mechanism that drives metastatic 
spread of breast and ovarian cancer cells.  
 
1.2 Breast cancer progression 
Breast tumor progression cannot be linked to mutations in a single pathway, and is rather a 
heterogeneous disease with different pathologies and molecular profiles.10,11 Initially, human 
breast tumors were categorized based on their histological features, but more recently gene 
expression profiling based on microarray analysis has made it possible to classify human 
breast tumors based on to their mRNA expression profile.12,13 Through mRNA profiles it is 
possible to divide tumors into four reproducible subtypes: luminal A, luminal B, basal and 
normal-like.12,13,14 Most subtypes of breast cancer are luminal tumors that share morphology 
with the inner epithelial cells facing the lumen of the mammary ducts. Luminal A tumors are 
positive for estrogen and the progesterone receptor (ER and PR) and negative for HER2, 
which makes them responsive to hormone treatment, and have a better prognosis.15,16  
Luminal B tumors are positive for HER2, and the prognosis is poorer due to increased cell 
growth.17 Basal like tumors do not share the luminal morphology but instead resemble 
myoepithelial ( or basal) cells lining the basement membrane of the mammary duct.18 Tumors 
with this type of morphology are more invasive and migratory.19 
Usually it is not the primary breast tumor that is the cause of death in patients, 
but rather metastatic spread to distant sites.20 Although the metastatic process is far from 
understood, advances with in the field have enabled us to grasp some of its complexity. Once 
tumor cells surpass the anti-proliferative control of tumor suppressor genes, such as p53, the 
retinoblastoma protein (RB) and Phosphatase and tensin homolog (Pten), and provide their 
own growth stimulatory factors they start to divide in an uncontrolled fashion.3,21,22,23,24,25 The 
general dogma and the explanation model of how tumors progress into an invasive state has 
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been that fast dividing tumor cells will accumulate more mutations that eventually allow them 
to acquire invasive properties. The balance between the activity of oncogenes, which may 
promote an invasive behavior, and tumor suppressors may play a role in dictating the invasive 
behavior of tumor cells.26,27,28 This still holds valid, but accumulating data point towards 
higher levels of complexity, and that intrinsic events cannot solely explain why certain breast 
cancer cells acquire invasive properties. Although tumor cells have lost their normal 
proliferative behavior, they are still growing in a context where many components come 
together to determine the course of progression (Figure 1).3,29 It is evident that both 
extracellular signals and intracellular events are important for the invasive behavior of tumor 
cells. 
Mammary ducts are encapsulated by both a basement membrane and the 
surrounding stromal compartment containing extracellular matrix. Thus, no preexisting 
natural passages exists that allow mammary epithelial cells to migrate through in order to 
reach the blood circulation.30 The basement membrane is an insoluble structure that is 
impermeable to large proteins, and the focal extracellular matrix is only permeable to cell 
movement during tissue remodeling, wound healing, inflammation and neoplasia. 31,32,33,34 A 
first step of progression is therefore for tumor cells to attach to the basement membrane 
which is mediated by specific glycoproteins such as laminins and fibronectin, through plasma 
membrane receptors.32,35,36 When attached, tumor cells secret hydrolytic enzymes that break 
up the basement membrane and start to degrade the matrix. 37,38,39 
As tumor cells pass the boarder of what usually separates the epithelial and 
mesenchymal compartment they are exposed to a new microenvironment that has the 
potential to further modify the tumor cells.40,41,42 The interaction with the tumor 
microenvironment is not a one way communication, and during tumor progression cancer 
cells also influence its own environment. This is evident, in the way tumor cells recruit bone 
marrow  derived cells such as leukocytes, neutrophils and macrophages to the tumor stroma, 
that in turn interact with tumor cells e.g. by producing cytokines.43,44,45 Under these 
conditions, when both the intrinsic factors of the tumor cells and the pro metastatic 
microenvironment act together, tumor cells can turn motile and invasive.38,46 
As tumor cells turn invasive, they have the capacity to migrate towards blood 
and lymphatic vessels and intravasate into the circulation.47 Tumor cells are known to 
produce pro angiogenic factors such as VEGF-A and VEGF-C, which promote both 
angiogenesis and lymphangiogenesis respectively.48,49,50 In the tumor micro environment 
blood and lymphatic vessels will in turn produce factors stimulating tumor cells, e.g. 
lymphatic vessels are known to produce chemokines that attract migratory tumor cells 51. The 
blood vessels that are formed in the tumor microenvironment are known to be leaky and often 
lack normal coverage by pericytes and vascular smooth muscle cells, which makes them 
permeable, and tumor cells can disseminate to the circulation.52,53 Lymph vessels are on the 
other hand designed for trafficking of immune cells, and can also act as a route tumor cells 
into the circulation.54,55,56 Once in the circulation, breast cancer cells have the capacity to find 
and to form metastasis in distant organs such as lung, bone and liver.57,58  
 
1.3 Epithelial Ovarian Cancer Progression 
Although a new classification of ovarian cancer, based on genetic profiles, has been 
developed dividing ovarian cancer into two broad groups of type I and type II, ovarian 
cancers are still divided into different subtypes including serious, endometrioid, clear cell, 
mucinous, and undifferentiated tumors based on morphological features. Serious carcionomas  
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Figure 1. Crosstalk between components in the tumor microenvironment and tumor 
cells drive tumor progression and invasion. Initially tumors grow in a confined epithelial 
compartment which is separated from underlying mesenchymal tissues by the basement 
membrane of the mammary duct. Throughout progression tumor cells secrete several factors 
such as EGF which establish (I) a paracrine circuit between tumor cells to sustain growth, and 
later as tumor cells enter the mesenchyme involve (II) recruitment of inflammatory cells with 
the capacity to either suppress or promote tumor progression, and (III) remodulation of the 
tumor stroma and interaction with stromal cells. Finally, tumor cells (IV) produce angiogenic 
factors that affect surrounding vasculature resulting in angiogenesis. In turn vessels produce 
chemokines serving as a gradient for tumor cells to migrate to. As tumor cells establish these 
connections, the route leading to blood circulation, becomes available.           
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are the most common types tumors of all EOC, and are divided into low (type I group) and 
high (type II group) grades tumors.6,59 
Different from many other types of cancers, ovarian cancer has generally not 
been linked to chemical carcinogens with mutagenic potential, and only a few mutations of 
e.g. p53, typical for serious high grade carcinomas, has been linked to onset of ovarian 
cancers.60,61,62 Epithelial cells of the ovary are known to proliferate at a low rate and generally 
stay quiescent. Only after ruptures of mature follicles to release oocytes, eptheilial cells have 
to proliferate in order to repair the disrupted ovarian surface.63 A large fraction of ovarian 
cancer develops at the epithelial subsurface of inclusion cysts, formed during ovulation.64  
Factors that increase the number of ovulatory cycles, such as early onset of 
menses and late menopause also increase the risk of acquiring ovarian cancer. Opposite, a 
reduced number of ovulatory cycles decrease the risk, and these factors include e.g. multiple 
pregnancies and prolonged lactation. It is difficult to detect early stages (I/II) of ovarian 
cancer since there are few specific symptoms of the disease and it is mostly during the later 
stages (III/IV), when the ovarian cancer already have started to spread that the diagnostics is 
being made.65,66,67,68,69 Once ovarian cancer cells are invasive, they can spread through both 
lymphatics, or via blood vessels to form metastasis in the parenchyma of the liver or lung. In 
addition ovarian cancer cells are also shed of from the ovary to form implants on the 
peritoneal surface, and this is made possible based on the anatomical structure, containing no 
barriers to prevent metastasis, in the peritoneal cavity.70,71,72,73   
 
1.4 Epithelial-Mesenchymal transition (EMT)  
Largely our bodies consist of epithelial and mesenchymal cells that have defined differences 
coupled to their physiological functions in the context of where they grow. Epithelial cells 
cover all outer and the most inner surfaces of tubular and glandular structures in the human 
body. Their functions include building a protective barrier against the outside environment, 
facilitate transport of substances across the epithelium, and mediate secretion in the glandular 
structures.30,74,75,76 Mesenchymal cells, including fibroblasts and smooth muscle cells, are on 
the other hand located in stromal compartments of the body, and are separated from epithelial 
cells by the basement membrane. These type of cells need to be motile during tissue repair 
and remodeling, have supportive and contractile functions.77,78,79 
Yet, during development epithelial cells trans-differentiate into mesenchymal-
like cells through Epithelial-Mesenchymal transition (EMT). Cycles of EMT and the reverse 
mesenchymal-epithelial transition (MET) is needed for proper formation of the embryo.5,80,81 
However, EMT can also be reactivated in pathologies including cancer and fibrosis.4,82  
During EMT, epithelial cells lose apical-basal polarity and their cell-cell adhesion to 
neighboring epithelial cells, and convert to mesenchymal-like cells that are characterized by 
front-back polarity, which allows cells to migrate in a directional manner through 
extracellular matrix.76,83 In cell culture, EMT is a visible process under magnification, and 
from growing in a cobblestone-like monolayer, epithelial cells undergoing EMT adopt a 
spindle-shaped mesenchymal morphology. At a molecular level, EMT induces reorganization 
of cytoskeletal proteins, loss of junction proteins and polarity complexes, and increased 
expression of MMPs with the capacity to modulate the extracellular matrix.4,84,85 
Although EMT has been observed in many in vitro models of cancer cells, the 
significance of EMT during cancer progression and its relevance in human cancer has been 
debated, mainly because of lacking evidence of EMT in clinical cancer samples.5,86 It has 
proved difficult to distingue cancer cells with mesenchymal properties from other 
mesenchymal cells in the tumor stroma. However, observations from the invasive front reveal 
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cancer cells, expressing both epithelial and mesenchymal markers, which are spreading from 
the tumor mass into the adjacent stroma. Besides from breast cancer this has been observed in 
different types of cancers including colon, cervical, thyroid and ovarian cancer.87,88,89,90 
In addition, markers of EMT such as snail and slug have been shown to 
clinically correlate with disease relapse of both breast and ovarian carcinoma.91,92 EMT has 
also been linked to basal-like, and metaplastic breast carcinoma and higher malignancies 
grades, again indicating that EMT worsen the clinical outcome.93 Induction of EMT is 
induced by many different growth factors both during development and in cancer, and these 
includes include Notch, epidermal growth factor (EGF), hepatic growth factor (HGF), Wnt 
factors, and Transformer growth factor β (TGF-β). 94,95,96,97,98,99 Although several factors most 
likely cooperate to induce EMT in tumors, TGF-β stands out as a major EMT inducer in 
cancerous disease.100 
 
1.5 Transformer growth factor beta (TGF-β)  
There are more than 30 factors belonging to the TGF-β family and they can be divided into 
two branches, one including bone morphogenetic proteins (BMPs), anti-muellerian hormone 
(AMH), and growth and differentiation factors (GDFs), and the other consisting of nodal, 
lefty, activin, and TGF-β.101,102,103 These factors are diversely expressed throughout 
development and in adulthood, to at a early stage e.g. promote differentiation of stem cells to 
regulate the body axis formation, and later maintain the homeostasis of the human body.102,104 
Transforming growth factor beta ligands, TGF-β1, TGF-β2 and TGF-β3, are 
potent regulators of cell growth, differentiation and migration.105 The different TGF-β 
isoforms signals through type I, II, III TGF-β receptors (TGFβRI, TGFβRII, and endoglin) to 
initiate downstream signaling pathways.106,107 When TGF-β1 and TGF-β3 ligands are 
expressed and activated, through proteolytic cleavage or structural modifications in the 
extracellular matrix and at the cell membrane, they bind to TGFβRII. The activated TGF-β2 
ligand is however dependent on the presence of the endoglin receptor to be able to bind 
TGFΒRII with high affinity. When expressed, the TGF-β type 1 and type II receptors form 
homodimers in the endoplasmic reticulum (ER) and at the cell surface when ligands are not 
present. TGF-β ligands favor binding to TGFβRII homodimers forming a ligand-bound 
receptor complex that in turn has high affinity for binding to the TGFβRI receptors, resulting 
in an activated heteromeric signaling complex.106,108,109 Activin receptor-like kinase 5 
(ALK5) is the predominantly expressed TGFβRI in most cell types, and is activated by TGFβ 
binding to TGFβRII. Notably ALK5 signaling results in the activations of the transcriptional 
co-regulators SMAD2 and SMAD3, whereas ALK-1 or ALK-2 acitivate SMAD1, SMAD5 
and SMAD8.110,111,112  
The functional TβRII-TβRI heteromeric signaling complex is generally linked 
to human cancer, and it regulates the induction of downstream SMAD-dependent and 
SMAD-independent pathways.113 Activation of this receptor complex, cause receptor-
associated SMAD2 and SMAD3 to form homo and heterotrimeric complexes with the 
common mediator SMAD4. As these complexes forms they translocate to the nucleus where 
they regulate gene transcription and this is the canonical SMAD-dependent pathway of TGFβ 
signaling.114,115 However, SMAD factors themself only bind DNA with low affinity, and 
therefore need to cooperate with other transcription factors in order to gain high binding 
affinity to specific target genes.116 Various transcription factors, both activating and 
repressing gene expression are known to bind to the Smad complex, including forkhead, zinc-
finger, bHLH, homeobox, and AP1 transciption factors. 
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In addition to the canonical SMAD signaling pathways, SMAD independent 
TGFβ signaling networks are also activated by the TGFβRI-TGFβRII heteromeric complex, 
including Ras homolog gene family, member A (RHOA), Rat Sarcoma protein (RAS), Rho 
family, small GTP binding protein (RAC1), phosphatidylinositol 3-kinase (PI3K), Mitogen-
activated protein kinase, kinase, kinase 1 (MEKK1), and TGFβ activated kinase (TAK1) 
117,118 Activation of all these kinases induce various signaling cascades with capacities to 
promote different cellular processes.119,120 
 
1.5.1 Role of TGF-β in cancer  
Under normal conditions, the basal release of TGF-β is sufficient to sustain tissue 
homeostasis.109,121 Conversely, in damage tissue during injury, TGF-β is produced at high 
levels by cells in the stromal compartment, in order to control regenerative cell proliferation 
and inflammation.122,123 It is important to know, that these conditions are activated in tumors 
as well, and that TGF-β is abundant in the tumor microenvironment. During early stages of 
tumor progression TGF-β act as a premalignant suppressor, while at later stages instead 
promote invasive and metastatic processes. In order to understand the dual nature of TGF-β 
signaling in cancer, one needs to consider the dynamic and contextual aspects of TGF-β 
induced pathways (Figure 2).124,125,126,127 
Mutation in the genes encoding TGF-β receptors have been detected in cancer, 
but inactivation of TGFβRII in specific tissues rarely leads to spontaneous formation of 
tumors.128 In the mammary epithelium, deletion of TGFΒRII causes lobular-alveolar cell 
proliferation in mice 129, but no pathological changes in other types of epithelia.130 Rather, it 
is during oncogenic stress or tissue injury that the role of TGF-β in restricting epithelial 
growth becomes evident, and depletion of TGFβRII or SMAD4 accelerates the malignant 
progression or neoplastic lesions with oncogenic stimuli.131,132,133 This is observed in polyma 
virus middle-T (PyMT) oncogene driven mammary tumors, where deletion of TGFRII 
enhance carcinoma formation.129 The cytostatic response to TGF-β is mediated through 
inhibition of the cell cycle in the GI phase, through mobilization of cyclin-dependent kinase 
inhibitors and c-Myc suppression.134 In epithelial cells FoxO transcription factors targets and 
activate p15INK4b and p21CIP1 promoters, leading to inhibition of cyclinD-cdk4/6 
complexes through p15Ink4b and cyclinE/A-cdk2 complexes by p21Cip1.135,136  
 As tumors progress the character of the TGF-β response changes, cytostatic 
effects are lost and instead TGF-β increase invasion and induce EMT.137 As previously 
discussed, both intrinsic and extrinsic factors come into play when tumor cells turn invasive, 
and this is reflected in the TGF-β response. Many mediators of the non-canonical signaling 
cascade, downstream of the TGF-β receptor, are not exclusive to TGF-β signaling, but rather 
components utilized in different types of signaling systems. Thus, there are many signaling 
focal point that enable co-regulation of cellular responses between the TGF-β pathway and 
others induced by different growth factors in the tumor microenvironment. This is evident in 
the regulation of GSK-3β, known to inactivate EMT promoting transcription factors, and 
targeted for inactivation downstream of both TGF-β and Wnt signaling.138 Enhanced 
induction, through combined stimulation of TGF-β and other growth factors such as EGF and 
HGF has been observed. EGF and HGF both induce RAS signaling that activate 
RAF/ERK/MAPKinase pathways, leading to loss of cytostatic response to TGF-β and 
activation of EMT promoting transcription factors such as snail and twist through induction  
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Figure 2. SMAD dependent and independent pathways of TGF-β signaling, subjective 
to intracellular influence in cancer cells, determine the cellular response to TGF-β. 
Activation of the heteromeric receptor complex of TGF-βRI and RII upon TGF-β ligand 
binding results in the induction of SMAD-dependent signaling, involving formation of the 
SMAD complexes with other transcription factors (TFs), and SMAD-independent signaling 
mediated upstream by e.g. RHO-A, RAC, and RAS. Both signaling cascades are under the 
influence of many intrinsic factors that are altered in tumor cells, and oncogenic pressure and 
other growth factors have the potential to alter the cellular response of TGF-β from growth 
inhibition to EMT.       
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of high-motility group A protein 2 (HMGA2).139,140 Different members of the RAS protein 
family have been shown to induce EMT in various degrees.139,141,142 In addition to other 
signaling pathways, non-canonical TGF-β pathway is also under influence of oncogenic 
activity, whereas abnormal activity of oncogenes such as, Pten, p53, and C-MYC are known 
to promote EMT.143,144,145  
 The dependence of SMAD complexes to interact with other transcription 
factors to bind and regulate target genes indicates that canonical TGF-β signaling is 
contextual.113 Indeed, studies of TGF-β induced EMT has revealed several transcription 
factors interacting with the SMAD proteins to promote EMT, including both transcriptional 
repressors and activators. The outcome of Smad-dependent TGF-β signaling is therefore 
reliant on the transcription factors available in the target cell. In conclusion, EMT requires 
both that SMAD-independent signaling is altered due to oncogenic pressure or combined 
exposure from cytokines, and the right mix of SMAD interacting transcription factors in the 
nucleus of the target cell. 105,114,146  
 
1.6 Transcriptional regulation of EMT 
Activation of TGFβ signaling in breast cancer cells during pro-metastatic conditions can, as 
discussed, induce EMT. In order to carry out the specific changes in the tumor cells when 
they turn mesenchymal, it is required that mechanisms involved in transcriptional regulation 
are altered – that genes previously turned off are turned on, and the reverse. In order to 
regulate gene expression different systems has been developed in the cell, involving 
regulation of the transcriptional complex by transcription factors, epigenetic modifications, 
and post-transcriptional regulation.147 In transcriptional machineries, all of these factors work 
together to promote or maintain cellular functions and phenotypes. By now different 
transcription factors promoting EMT has been identified, including both transcriptional 
repressors and activators. Many of these factors have been shown to interact directly to co-
SMADs and are thus activated during TGF-β induced EMT.146,148  
During EMT transcriptional repressors will silence the expression of epithelial genes 
such as junction proteins. This is evident on the promoter of E-cadherin were Snail, Zeb and 
bHLH factors bind to repress the expression. 91,149,150,151 In the E-Cadherin promoter this is 
mediated through binding of these factors to E-box sequences with a 5´-CACCTG-3´core 
motif.92,152,153 Binding of factors from the Snail family is generally thought to repress 
transcription through recruitment of chromatin remodeling complexes that silence the gene, 
although they can, in a context dependent manner, activate target genes as well.154,155 Snail1 
is a major promoter of EMT in development and cancer, and overexpression alone is enough 
to induce EMT in cell culture.156,157 Snail overexpression has been shown to induce other 
repressors and is upregulated early during TGF-β induced EMT. In fact, a peak of Snail1 
expression can be seen early after TGF-β stimulation in cultured epithelial cells.158  Even if it 
is evident that factors of the Snail family regulate each other, these two aspects might suggest 
that Snail1 is essential to kick start EMT. 
Transcriptional activators promoting EMT, on the other hand, will bind and increase 
the expression of mesenchymal genes and includes factors like B-catenin, AP-1, SP-1 and 
NFkB transcription factors. B-catenin, activated by Wnt signaling, interacts with TCF4/LEF 
transcription factors to induce genes involved in EMT, such as Vimentin and Snail2.159,160 
AP-1 promotes the expression of MMPs and is formed as heterodimers of jun-fos/fra proteins 
or as jun-jun homodimers and is known to promote invasiveness and metastatic capacity of 
cancer cells.161 As an activator of Snail1 and Twist expression NFKβ overexpression is 
sufficient to induce EMT in mammary epithelial cells.162 
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Figure 3. A transcriptional switch during EMT involves both epithelial and 
mesenchymal transcriptional activators and repressors. One central part of the 
transcriptome is transcriptional regulation. To maintain the epithelial phenotype a set of 
different genes needs to be kept active in the cell involving polarization, cell-cell adhesion, 
and in ducal structures secretion. As epithelial cells form transcriptional repressors also needs 
to inactivate expression of genes promoting a non-epithelial cell fate, including mesenchymal 
genes. Reversed circumstances are found in mesenchymal cells where genes involved in the 
mesenchymal cell functions are activated and other genes repressed.  During EMT, factors 
such as TGF-β switch the transcriptional machine of the cell, turning off epithelial 
transcription factors and turning on mesenchymal. This leads to phonotypical changes 
promoting a migratory behavior of otherwise stationary epithelial cells.   
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Although the transcriptional inducers of EMT have been well characterized and 
studied there is less known about transcription factors able to prevent EMT. Even so, it is 
logical to assume that transcriptional programs activated to promote and maintain the 
epithelial phenotype needs to be inactivated during EMT. In line with this, different 
transcription factors known to promote epithelial differentiation during development have 
been shown to prevent invasive behavior of tumor cells and also EMT. Due to the initial 
epithelial programs in the tumor cells e.g. KLF, BRCA, ELF family members have been 
known to inhibit EMT through activation or repression of target genes. Still, further 
evaluation is needed to determine the capacity of epithelial differentiation factors to prevent 
and even revert EMT.163,164,165,166,167,168  
 
1.6.1 CCAAT-enhancer binding protein beta 
The CCAAT-enhancer binding protein (C/EBP) family transcription factors, consisting of 6 
members (α-γ), are known to play crucial role in different cellular events including cellular 
proliferation, differentiation, metabolism and inflammation.169 All factors within the C/EBP 
family contain the same leucine zipper domain at the C-terminus and they all share the 
capacity to bind to the CCAAT sequence of DNA. Although they all bind to the same 
sequence, the N-terminal part, which varies in size, of the C/EBP proteins enables different 
type of interactions and actions once bound to DNA.170 
The expression of C/EBP proteins varies throughout different tissues of the 
human body, and in mammary epithelial cells C/EBPβ has been identified as differentiation 
factor towards luminal cell fate in the mammary epithelium and as regulator of branching 
morphogenesis.170,171,172 Through alternative splicing C/EBPβ is produced in three isoforms, 
liver activation protein 1 and 2 (LAP1 and LAP2) both two transcriptional activators 
containing transactivation domains, and the shorter isoform liver inactivation protein (LIP). 
LIP is generally considered to act as a repressor of C/EBPβ activity since it lacks the 
transactivation domain.173 
In breast cancer C/EBPβ has been described as deregulated, and in some cases 
inducing proliferation of tumor cells174,175, but the role of C/EBPβ in cancer is not fully 
known. Different isoforms of C/EBPβ, and the ratio of LIP and LAP has shown to be of 
importance.176,177 In line with this, inactivation of C/EBPβ activity due to high LIP/LAP ratio 
is a mechanism of evasion from the cytostatic TGF-β resonse in breast cancer. In this study 
C/EBPβ was shown to interact with Smad complexes to activate the expression of INK4b, 
encoding p15INK4b, a mechanism that was lost in metastatic breast cancer cells from pleural 
effusions.178 
 
1.6.2 Forkhead box P4  
Forkhead box (Fox) proteins, a family that all contain a common forkhead box DNA binding 
domain are evolutionally conserved transcription factors. In total there are 19 subfamilies 
with around 50 genes, and they play various roles in different biological processes during 
development including differentiation, proliferation and apoptosis. Certain members of the 
fox family of proteins have been linked to epithelial plasticity of cancer cells and deregulated 
expression of these proteins has been related to increased malignancy and metastatic capacity. 
179,180 
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Forkhead box P4 (FoxP4) found to be expressed in epithelial cells in different 
tissues, and have been described to play important roles in mediating differentiation.181,182,183 
184 Foxp4 is expressed in the pulmonary epithelium were it promotes differentiation of 
secretory epithelial cells through inhibition of goblet cell differentiation.182 In neuroepithelial 
cells Foxp4 is known to transcriptionally repress N-cadherin in order to promote epithelial 
differentiation.185 In mammary epithelial cells Foxp4 has been identified as a core 
transcription factor based on its enriched expression.186 Although no studies have been 
performed specifically on the role of foxp4 in women´s cancer it has been shown to be a 
target for oncogenic translocation in breast cancer.187 In addition, it has been identified as a 
susceptibility locus for prostate cancer, and decreased levels of Foxp4 has been reported in 
kidney cancer.184,188 
 
1.7 Tight junctions  
Epithelial cell layers form barriers that protect multicellular organisms from the external 
environment. Epithelial integrity is maintained by tight junctions, adherens junctions and 
desmosomes. Adherens junctions are formed by E-cadherin,189 while transmembrane 
components of tight junctions include claudins, occluding,190 and Ig-like proteins like the 
coxsackie- and adenovirus receptor (CAR), the junction adhesion molecules (JAMs) and 
CAR-like mambrane protein (CLMP).190,191,192 Tight junction proteins such as occludins, 
claudins and the recently identified members of the large Ig superfamily, e.g. CAR, are all 
mediators of cell-cell adhesion. Tight junctions affect many cellular functions, including 
cytoskeletal dynamics, polarized vesicle trafficking and proliferation.193 TJs control 
physiological flux of ions and solutes across the barrier and are regulated by different growth 
factors, cytokines and hormones.194 
Transmembrane components of TJs are located to the apical side of the cells 
facing the lumen, and binds to scaffolding proteins that have an intracellular location close to 
the membrane.  In turn scaffolding proteins are bound to the actin filament, and together this 
forms a netlike structure that spans across the epithelium constituting the TJ 
barrier.195,196,197,198 Interestingly, many kinases, phosphatases and transcription factors have 
been described to localize at the TJs, indicating that not only do TJs regulate extracellular 
conditions and events, but also serve as a hub for intracellular signaling.199,200 Certain 
proteins, such as RAC, and protein kinase C (PKC) are recruited to the TJs to perform their 
functions, 201 others like transcription factors c-jun and c-fos are inactively stored at the TJs. 
202 Upon deregulation or disruption of the TJ barrier factors belonging to the TJ hub are both 
activated and inactivate, possibly as a mechanism for the cell to quickly response to changed 
conditions.201,203 
   
1.5.1 Coxsackie- and adenovirus receptor (CAR) 
The coxsackie- and adenovirus receptor (CAR) is a member of the large immunoglobulin-
like receptor family and a component of epithelial tight junctions and was first identified as a 
receptor for coxsackie B and type C adenoviruses. 204,205 Consequently, along with some 
other TJs, CAR serve as an entry point for viruses.206 TJs all share the ability to promote cell-
cell adhesion, and many of the TJ components have been proven to be dispensable. CAR on 
the other hand is, together with a few other TJs, vital both during development and in adult 
mice. Depletion of CAR in development leads to malfunction of the heart, as CAR mediates 
contact between the discs of cardiomyocytes.191,207 Knock down of CAR in adult mice leads 
to dilation of the instestinal tract, acinar-to-ductal metaplasia of the exocrine pancreas, and 
cause lethality.208 CAR is downregulated early during TGF-β induced EMT, in a similar 
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fashion to E-cadherin by master EMT regulators, but the role of CAR in the EMT response is 
not clear.209 
 
 
1.8 Treatment of women´s cancer 
One of the major hallmarks of cancer is the evasive behavior of tumor cells towards growth 
inhibitory and an apoptotic stimulus compared to normal cells, and was recognize early on in 
the field of oncology.3 In the mid 20th century it was discovered that alkylating agents 
originally derived from mustard gas, had the capacity to target fast dividing tumor cells, and 
once injected into patients with leukemia had a beneficial outcome increasing survival.210 
This kind of treatment, now including several agents essentially all targeting fast dividing 
cells, was termed chemotherapy, and is commonly used to treat patients with different types 
of cancerous diseases worldwide.211           
 In addition to chemotherapy, both radiation therapy, and removal of the tumors 
through surgery is the standard line of treatment for cancer.212,213 In ovarian cancer the bulk 
tumor is removed through cytoreductive surgery, which means that the entire visible tumor is 
removed and followed by adding heated chemotherapy drugs to the operated area. Breast 
tumors are removed surgically and followed up with chemotherapy afterwards. Based on the 
clinical features of tumors, a scheme and agents for chemotherapy is adopted individually for 
patients of breast and ovarian cancer.51,214 The commonly used drugs for breast cancer 
treatment include the anthracyclines doxorubicin and epirubicin, and the taxanes paclitaxel 
and docetaxel. In some cases these are used in combination with other drugs, like fluorouracil 
(5-FU), cyclophosphamide, and carboplatin. For ovarian cancer the standard approach is to 
combind plantinum compounds such as cisplatin or carboplatin with taxane drugs like 
paclitaxel.215,216   
Cisplatin, the drug studied in this thesis, cause antitumoral effects through its 
ability to for DNA breaks and pronounced DNA damage, mainly in proliferative cells. 
Compared to carboplatin, there are more side effects in non proliferative tissues associated 
with cisplatin, including oto-, nephro and neurotoxicity.217,218 Besides from DNA damage, 
cisplatin induces apoptosis through non-nuclear targets, with mitochondria as a major one. 
This is due to the acute effects of cisplatin inducing reactive oxygen species (ROS) and 
binding to mitochondrial DNA (mtDNA).219   
 In ovarian cancer, 70% of the patients will respond to platinum- and taxane-
based chemotherapy after surgery, and in 50% of these patients no cancer can be detected 
after 5 month of treatment. In breast cancer approximately 20% of treated patients have a 
relapse over a 10 year period. Although the reduction of visible tumor is present in EOC, 
75% of all patients will relapse within 3 years. For triple negative breast cancer 20% of 
patients will relapse with signs of distant metastasis.6,220,221 In EOC and breast cancer 
recurrent cancer cells are difficult to treat since they have developed multiresistency towards 
chemotherapy.82,222 These facts indicate that further alternative approaches for cancer 
treatments are necessary in order to cure patients from the disease. As the field of cancer 
research is progressing, and other hallmarks of cancer besides cell proliferation and growth 
are being explored, many new therapies are under development e.g. immunotherapies and 
anti-angiogenic treatments.223,224,225      
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2   AIMS OF THE STUDIES 
 
• To charachterize ovarian cancer cells resistant to cisplatin treatments in terms of EMT 
and cancer stem cell properties 
 
• To Study the role of C/EBPβ, as a transcriptional activator of junction proteins, in 
TGF-β induced EMT in breast cancer 
 
• To investigate role of Foxp4, as a transcriptional repressor of mesenchymal genes, in 
TGF-β induced EMT in breast cancer 
 
• To study the role of CAR in regulating the EMT response to TGF-β in breast cancer 
cells 
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3   RESULT AND DISCUSSION 
 
3.1 Paper I 
Repeated cisplatin treatment can lead to a multiresistant tumor cell population with 
stem cell features and sensitivity to 3-bromopyruvate 
Chemotherapies have mostly been developed to target the cell proliferative behavior of tumor 
cells. However, EOC cells frequently get resistant to this kind of therapy and it is still not 
clear to which features of the EOC cells that resistance is coupled to, but data indicate that 
cisplatin resistant cells have more aggressive properties. The aims of this study was therefore 
to (i) investigate whether EOC cells induced to become resistant to cisplatin treatment 
developt EMT and cancer stem cell characteristics, and (ii) study alteration in mitochondrial 
status of these cells, since cisplatin has non-nuclear target effects.  
First, human ovarian carcinoma, SKOV-3, cells were repeatedly treated with 
cisplatin for long term, to generate resistant (R) cells, or treated with EtBr to make cells 
deficient in mitochondrial DNA (ρ0). To verify chemoresistanant features, SKOV-3-R cells 
were treated with other platinum drugs including carboplatin, paclitaxel and 5-FU. Based on 
IC-50 values after 72 h of treatment, SKOV-3-R displayed many fold increased resistance to 
these drugs compared to parental SKOV-3 cells. These data confirm that the repeated 
cisplatin treatment generated multi resistance cells. In contrast SKOV-3-ρ0 cells did not 
display increased resistance. Known genes for drug resistance, Bcl-2, and the efflux protein 
ABCG2, was not upregulated in SKOV-3-R cells. 
Leading up to this collaborative effort, was the finding that SKOV-3-R cells 
displayed a more mesenchymal morphology, and my part was primarily to assist further 
investigation of this finding. Western Blot analysis showed decreased levels of E-cadherin 
and increased levels of Vimentin and Twist in SKOV-3-R cells compared to parental and ρ0 
cells. Immunoflourescent staining confirmed increased nuclear staining of Twist and Snail in 
SKOV-3-R cells, suggesting that these factors might contribute to induction of the EMT 
phenotype in resistant cells. Using an automated xCelligence® device, motility of SKOV-3-R 
cells was evaluated, and in comparison to parental cells, displayed greater motility.  
Since a link between EMT and cancer stem cells (CSC) has previously been 
described,226 we were also interested to study expression of CSC markers and the capacity to 
form mammospheres in SKOV-3-R cells. In line with this, western blot analysis showed 
upregulation of known CSC markers CD44, CD117 and ALDH1 in SKOV-3-R cells 
compared to parental and ρ0 cells, but not the stem cell markers Oct-4 and Nanog. Functional 
sphere forming assays, on low binding cell culture plastics, showed that SKOV-3-R had 
higher self-renewal capacity and compared to parental and ρ0 cells did not lose viability over 
time. These data suggest that multi-resistant ovarian cancer cells after cisplatin treatment 
show CSC and EMT characteristics.  
Based these findings, we were interested in investigated ways to target the stem 
cell and EMT features of the SKOV-3 cells in order to decrease cellular viability to drug 
treatment. Since tyrosin kinase receptor CD117 was one of the more upregulated markers in 
SKOV-3-R cells this was our first target. CD117 is a blocked by imatinib mesylate (gleevec), 
thus SKOV-3-R cells were treated for 48 h with the gleevec singly and in combinations with 
cisplatin, whereafter they were allowed to recover in drug-free medium for another 72 h. In 
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these experiments imatinib mesylate, alone or in combination, had no effect on growth at any 
time point in SKOV-3-R. Similar negative results were obtained with ISCK03 (5 µM), 
another inhibitor of CD117 that did not lower the IC50 value for cisplatin in SKOV-3-R cells..   
Taken together these results indicate that targeting CD117 did not restore 
toxicity to cisplatin in SKOV-3-R cells. Another feature of the SKOV-3-R cells discovered 
throughout the project was that the mitochondrial status was changed, and SKOV-3-R cells 
had increased mitochondrial mass compared to parental cells detected with potential-
independent MitoTrackerGreen dye. This was supported by increased levels of the nucleus-
encoded mitochondrial proteins voltage-dependent anion channel (VDAC) and cytochrome c. 
Since mitochondrial metabolism and cell death is known to be regulated by VDAC, partially 
through binding of hexokinase-II (HK-II), we further investigate HK-II levels in the SKOV-
3-R cells. Indeed we found upregulated levels of HK-11 in SKOV-3-R cells, and to a larger 
extent in SKOV-3-ρ0 cells, which makes sense since they are devoid of ETC and respiration. 
3-bromopyruvate (3-BP) is small molecule that a have been shown to have antitumoral 
effects by targeting and inducing dissociation of HK-II, and we were curious to evaluate if 
SKOV-3-R was sensitive to this compound. Treatment with 3-BP in one dose for 48 h was 
enough to reduce proliferation in both partental and SKOV-3-R cells, however while parental 
cells could resume to normal growth under drug-free conditions during the next 72 h, SKOV-
3-R cells was unable to. In addition, we found that 3-BP enhanced the antiproliferatvie effects 
of cisplatin. 
Combination of drugs targeting different features of tumor cells and their 
environment, have shown promise to treat cancer, and this study belongs to this category of 
studies. In the described case, abnormal metabolic activity of HK-II in SKOV-3 cells, made 
them vulnerable to its inhibitor 3-BP. However in our attempts to target EMT and CSC 
features of the SKOV-3 cells, through CD117 inhibition, we had no effect. Further 
exploration and understanding of these processes in tumor cells might therefore be needed to 
be successful in such an endeavor.          
 
3.2 Paper II 
MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to 
epithelial-mesenchymal transition, invasion and metastasis in breast cancer. 
As previously discussed, multiple factors are involved in tumor progression and the induction 
of EMT, and needs to be taken into consideration in studies conducted on EMT. Although 
this is rational, TGF-β stands out as a major inducer of EMT and is frequently associated with 
EMT both in vitro and in vivo in cancer and development. Interestingly, TGF-β signaling has 
opposite roles in cancer, acting as a tumor suppressor at early a stage, and as a promoter of 
malignancy and EMT at a later stage. Data also suggest that the switch in TGF-β response 
actually revolves around factors involved in EMT, and the TGF-β switch might be a premise 
for EMT in cancer. Following this line of though, and based on its previously described role 
in the cytostatic effects of TGF-β and being a differentiation factor in mammary epithelial 
cells, C/EBPβ emerged as interesting transcription factor to study in EMT, and in paper II we 
aimed to test the hypothesis that loss of C/EBPβ has a preventative role against TGF-β-
induced EMT in breast cancer.       
In order to study C/EBPβ expression in breast cancer cells with a less 
differentiated phenotype potentially undergoing EMT, we preformed immunoflourescent 
staining on human breast carcinoma samples and did subsequent confocal microscopy 
analysis. E-Cadherin, known to be lost in invasive cancer and common marker for EMT, 
was stained in combination with C/EBPβ. In breast cancer samples of well-differentiated 
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ductal carcinoma in situ (DCIS), strong staining of E-cadherin was detected at cell–cell 
junctions, and pronounced nuclear C/EBPβ staining was detected in the breast cancer cells. 
In a series of eight invasive ductal breast carcinomas, which had been classified according 
to their status of estrogen receptor, progesterone receptor and HER2, we next analyzed the 
expression of E-cadherin and C/EBPβ. We found decreased expression of E-cadherin in 
areas of triple-negative tumors, and, in total, lower levels of E-cadherin in triple-negative 
tumors compared to tumors positive for estrogen receptor, progesterone receptor and 
HER2, or only HER2. Nuclear staining for C/EBPβ was reduced in triple-negative tumors 
and linear regression analysis revealed a significant correlation (P=0.0011) between the 
expression of E-cadherin and C/EBPβ in all tumors analyzed. Further analysis 
demonstrated significantly decreased expression of C/EBPβ in E-cadherin-negative areas 
compared with E-cadherin-positive areas of the triple-negative breast tumors. In support of 
these finding we could in a mouse model of mammary cancer progression, with mice 
overexpressing the polyoma virus middle T antigen under the mouse mammary tumor virus 
promoter (MMTV-PyMT mice), find that C/EBPβ expression was lost at an advanced stage 
of cancer at the age of 10 to 14 weeks. Co-staining for E-cadherin and C/EBPβ in tumor 
sections from 10- and 14-week-old MMTV-PyMT mice showed loss of C/EBPβ expression 
in E-cadherin-negative areas compared with E-cadherin-positive. 
To explore the mechanisms of C/EBPβ loss in breast cancer, we used an established 
model of TGF-β1-induced EMT in namru mouse mammary gland (NMuMG) epithelial 
cells. Treatment with TGF-β1, induce visible signs of EMT after 24 h in NMuMG cells, 
and at 48 h detectble changes in protein level of epithelial markers such as E-cadherin and 
gain mesenchymal markers e.g. Vimentin are present. Immunoflourecent analysis of 
untreated NMuMG cells showed typical nuclear staining of C/EBPβ, which was lost in cells 
treated with TGF-β1 to undergo EMT. Further western blot analysis of C/EBPβ showed 
that all three C/EBPβ isoforms (LAP1, LAP2 and LIP) were decreased in TGF-β1-treated 
NMuMG cells, and no obvious change in the ratio between LIP and LAP was detected. By 
comparison, TGF-β1 treated mouse mammary EpH4 cells, lacking the capacity to undergo 
EMT, did not induce loss of C/EBPβ, suggesting that loss of C/EBPβ is an EMT specific 
event.  
Interestingly C/EBPβ was not downregulated at RNA level indicated by qPCR 
analysis, suggesting post transcriptional regulation of C/EBPβ during EMT. Based on other 
studies, showing that Cebpb mRNA is a target of miR-155 in B-cells and 
macrophages227,228, and that miR-155 is a known oncomiR in cancer 229, we hypothesize 
that miR-155 might be a repressor of C/EBPβ during TGF-β1 induced EMT in breast 
cancer. To test this, NMuMG cells were transfected with a synthetic miR-155 inhibitor 
(50 nM), in combination with TGF-β1 treatment to study whether the presence of the miR-
155 inhibitor would rescue C/EBPβ expression. We found that in the presence of the miR-
155 inhibitor, the expression of C/EBPβ was increased at baseline, and less repressed 
during EMT. On the contrary, transfection of NMuMG cells, with a synthetic miR-155 
mimic (50 nM), resulted in decreased levels of C/EBPβ at baseline, and further repression 
after TGF-β1 treatment. Further analysis by qPCR showed that the expression levels of 
miR-155 were approximately 4.5-fold higher in NMuMG cells compared with EpH4 cells 
at baseline, and increased in NMuMG cells subjected to TGF-β1. This experiment also 
shows that the expression level of C/EBPβ (all isoforms) was considerably higher in EpH4 
cells compared with NMuMG cells.  
To study whether miR-155 mediated loss of C/EBPβ could sensitize breast cancer 
cells to TGF-β1 induced EMT, we set up a series of gain and loss of function experiments. 
Lentivirus mediated knock down of C/EBPβ through overexpression of small hairpin RNA 
(shRNA), lead to reduced baseline expression of E-cadherin and CAR, and potentiated 
TGF-β1 induced EMT, indicated by increased levels of vimentin and further suppression of 
E-cadherin and CAR expression. Conversely, transient overexpression of LAP2 in 
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NMuMG cells resulted in increased mRNA levels of Cdh1 and Cxadr at baseline, and less 
repression of both genes in response to TGF-β1 (2 ng/ml, 24 h).  
Based on these data we wanted to examine the potential of C/EBPβ to revert cells 
maintaining an EMT program back to the epithelial phenotype. In order to do so we treated 
NMuMG cells with TGF-β1 for more than 14 days (long-term), which had been reported to 
induce robust EMT and evasion from the cytostatic effects of TGF-β. Next we transiently 
overexpressed LAP2 in these cells, which lead to increased protein levels of epithelial 
markers E-Cadherin and CAR. On the contrary, overexpression of LAP2 did not influence 
the expression of mesenchymal EMT markers, including master regulators such as Zeb1, 
Slug, Snail and Twist. Together, these data indicate that reactivation of C/EBPβ only 
partially revert EMT cells back to their epithelial origin.   
Next we wanted to study if C/EBPβ levels in breast cancer cells would also affect 
the invasive behavior in vitro and the metastatic process in vivo. To do so, we used the 4T1 
mammary tumor model, a TGF-β driven model of metastasis, and preformed loss of 
function experiments. Lentivirus mediated knock down of C/EBPβ resulted in less 
expression of E-cadherin and increased expression of vimentin, and shCebpb expressing 
cells were more invasive in boyden chamber assays towards a TGF-β1 gradient. We went 
on injecting 4T1 cells expressing shControl or shCebpb subcutaneously into the flank of 
syngeneic BALB/c mice, tumors were formed and surgically removed after 2 weeks. 
Measurements of tumor growth indicated that tumors with repressed cebpb expression grew 
slower compared to control, but two month after tumors were surgically removed had 
formed more metastasis in the lungs.    
Our results indicated that C/EBPβ levels could alter the outcome of TGF-β signaling 
promoting EMT, invasion and metastasis in breast cancer, and we were curious to study the 
underlying mechanisms further. Our results had shown that knock down C/EBPβ was 
enough to reduce expression of E-cadherin and CAR, which lead us to hypothesize that 
C/EBPβ can modulate the EMT response of TGF-β by acting as a transcriptional activator 
of junction proteins.  
 In order to address this hypothesis, computer-based software was used to scan 
for putative binding sites for C/EBP transcription factors in the genomic DNA promoter 
sequences of several genes encoding junction proteins, and sites were found in the 
promoters of following genes: Cdh1, Cxadr, Cldn3, and Ocln. Further, chromatin 
immunoprecipitation (ChIP) assays showed specific C/EBPβ binding to the regions of 
putative binding sites in the promoters of the Cdh1 and Cxadr genes in NMuMG cells. 
Since C/EBPβ had the capacity to bind to these two promoters we performed promoter 
reporter assays to determine if C/EBPβ also could activate them. These experiments 
showed that overexpression of C/EBPβ activated the Cdh1 promoter by twofold and the 
Cxadr promoter by 2.5-fold and that overexpression of LAP2 by itself was more potent than 
C/EBPβ to activate the promoters. Knock down of C/EBPβ resulted in less mRNA 
expression of cdh1 and cxadr, while overexpression induced the expression. Treatment of 
TGF-β1 to induce EMT, also caused C/EBPβ to dissociate from the cdh1 and cxadr 
promters. 
This study, in combination with the previous study on cytostatic response, 
suggests that C/EBPβ, a transcription factor promoting epithelial cell differentiation, have 
the capacity to inhibit EMT and restore the TGF-β response towards growth inhibition. 
Even so, C/EBPβ lacked the capacity to fully revert EMT, which might indicate that 
reversion of EMT, based on transcriptional regulation, demands altered action of other 
transcription factors as well.   
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3.3 Paper III  
Foxp4 controls EMT in breast cancer cells by acting as a transcriptional repressor of 
Snail1 
 
During the course of our studies we identified Foxp4, a novel member of the family of 
Forkhead box (Fox) P transcription factors, as a C/EBPβ target gene in mammary epithelial 
cells (data not shown). Based on this, and recent published findings showing that Foxp4 is a 
repressor of N-cadherin in neuroepithelial cells, we initiated studies to elucidate whether 
Foxp4 could play a role in regulating EMT in breast cancer. 
First we took a bioinformatical approach and performed meta-analysis of publically 
available gene data sets on breast cancer and normal mammary gland material, and we 
followed up with immunohistochemistry analysis on invasive breast cancer patient samples. 
The meta-analysis revealed that Foxp4 expression was decreased in invasive breast 
carcinoma compared to normal mammary gland, and a weak positive correlation between E-
Cadherin expression and Foxp4 in invasive breast carcinoma samples. Immunohistochemical 
staining also supported these results showing that nuclear Foxp4 expression was decreased in 
invasive breast cancer and that cells expressing lower levels of E-Cadherin had significantly 
decreased levels of Foxp4.  
These data suggested that foxp4 expression is lost in invasive cancer compared to 
normal mammary epithelium, an indication that maybe oncogenic conversion of epithelial 
cells is a causative effect of foxp4 loss. In particular, oncogenic variants of RAS have been 
linked to malignant progression and EMT of breast cancer cells. Thus, in order to study foxp4 
expression during tumor progression driven by oncogenic HaRAS, we used a transgenic 
mouse model of inducible MMTV-HaRAS expression in Balb/c mice. Mice of this model 
develop mammary tumors that progress into invasive tumors with signs of EMT properties, 
and metastasize to the lungs. As tumors formed after 1-3 weeks of HaRAS activation, we 
observed downregulation of Foxp4 expression in the nuclei of cancer cells, and after 4 weeks 
of tumor progression we had close to non-detecteble levels of Foxp4 in the tumor cells. To 
study whether HaRAS activation directly affects FoxP4 expression, we used adenovirus 
vectors to transiently overexpress HaRAS and KRAS in mouse mammary epithelial, EpH4, 
cells. Overexpression of either HaRAS or KRAS for 48 h resulted in decreased expression of 
FoxP4, both at mRNA and protein levels. 
In line with the studies performed on C/EBPβ, we wanted evaluate if foxp4 could 
impact TGF-β induced EMT, something that was also supported by our findings that foxp4 
expression was decreased in invasive human breast cancer cells with signs of EMT. Again we 
used NMuMG cells, and induced expression of Foxp4 shRNA through lentivirus 
transduction. Knockdown of Foxp4 by itself was enough to induce an E-to-N-cadherin switch 
in NMuMG cells, and cause increased levels of vimentin. Further, treatment with TGF-β1 for 
48 h resulted in a more pronounced EMT phenotype in shFoxp4 compared to shControl 
expressing NMuMG cells. Knock down of Foxp4 also lead to increased invasive behavior of 
NMuMG cells in the boyden chamber assay, were cells migrated in matrigel towards a TGF-
β1 gradient.        
As an additional experiment to further study the implications of reduced Foxp4 
expression during EMT, we did knocked down of Foxp4 in mouse mammary EpRas tumor 
cells. Once injected into syngeneic BALB/c mice, these cells have the capacity to undergo 
EMT. Knockdown of Foxp4 in EpRas cells resulted in increased expression of N-cadherin 
and vimentin, reduced expression of E-cadherin and CAR, and increased invasive capacity in 
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vitro. Although knock down of Foxp4 did not affect tumor growth, immunofluorescence 
staining indicated that cells in tumors formed by shFoxp4 expressing cells expressed lower 
levels of E-cadherin and higher levels of N-cadherin compared to shControl tumors. 
Together, these results support the hypothesis that that loss of Foxp4 promotes EMT in both 
normal and transformed mammary epithelial cells.  
Since Foxp4 is a known transcriptional repressor, but reverted both mesenchymal and 
epithelial genes during EMT, we hypothesized that Foxp4 transcriptionally repress one or 
several master regulators of EMT. To test this, we analyzed the expression of a set of master 
regulators including Snail1, Snail2, and Zeb1 in NMuMG cells after Foxp4 knock down. In 
NMuMG cells expressing shFoxp4, mRNA levels of Snail1, Snail2, and Zeb1 were increased 
compared to control shRNA. To evaluate if all these genes were directly repressed by Foxp4, 
or if the reduction was due to secondary effects, we instead transiently overexpressed Foxp4 
and analyzed the mRNA expression at earlier time points. At a 24 h time point of Foxp4 
overexpression no significant changes could be detected in mRNA levels for any of the 
genes, however at 48 h both cdh2 and snai1 were significantly repressed but not snai2 and 
zeb1.  
As these results suggested that Snail1 might be a direct target of Foxp4, we did 
sequence analysis on the 1000 base pair promoter sequence located upstream of the first ATG 
of the mouse Snai1 gene, revealing three putative FoxP binding sites. Transfecting cells with 
luciferase reporter constructs containing full length or truncated versions (575, 300, 100 bp) 
of the snai1 promoter in combination with Foxp4 overexpression vector resulted in repression 
of the full length snai1 promoter. The repression by Foxp4 was only rescued when all three 
putative binding sites were truncated. In addition, ChIP assays verified binding of Foxp4 to 
the regions of these 3 putative binding sites in the snai1 promoter in NMuMG cells.  
Knock down of Foxp4 in NMuMG cells resulted in increased mRNA levels of Snail1 
at baseline compared to control cells and based on these results we next asked whether Snail1 
also would be differently expressed during EMT in Foxp4 depleted cells. Following 
treatment with TGF-β1 for 24h the induction of Snail in cells with impaired Foxp4 expression 
was robustly increased compared to control cells. At protein level the difference could be 
observed between control and Foxp4 knock down cells after 48 h TGF-β1 treatment, however 
no detectable levels of Snail1 was found at baseline in both control and knock down. These 
data may indicate that increased RNA levels of Snail1 alone is not enough to increase protein 
levels of Snail1, and suggest that post transcriptional stabilization of Snail1 also needs to 
occur, something that is known to happen during TGF-β1 induced EMT. Finally, 
immunohistochemical staining of human breast cancer samples showed increased staining of 
Snail1 in Foxp4 negative areas of tumors, perhaps implementing a clinical relevance of this 
mechanism since Snail1 is linked to a worse clinical outcome.    
As a next step we were interested in investigating if reactivation of Foxp4 in breast 
cancer cells could revert cells back from EMT. Transient overexpression of Foxp4 in 
NMuMG cells resulted in slightly reduced levels of N-cadherin and vimentin, both at baseline 
and upon TGF-β1 treatment for 24 h. In addition, downregulation of E-cadherin and CAR 
was partially rescued after TGF-β treatment in Foxp4 overexpressing cells compared to 
control. These data suggest that Foxp4 can inhibit induction of EMT. Next, we wanted to 
determine whether overexpression of Foxp4 could revert EMT in human breast cancer cells. 
For these studies, we used invasive human breast cancer MDA-MB-231 cells, which are 
known to display EMT properties. Stable, lentivirus-mediated overexpression of Foxp4 in 
MDA-MB-231 cells resulted in reduced expression of Snail1, N-cadherin and Vimentin, and 
increased expression of CAR. E-cadherin was not detected in these cells. These results 
indicated that overexpression of Foxp4 was sufficient to induce MET in human breast cancer 
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cells. In line with this, we found that Foxp4 overexpressing MDA-MB-231 cells were less 
invasive in the boyden chamber assay towards a TGF-β1 gradient.  
Based on our results, it will be of further interest to evaluate if Foxp4 overexpression 
in MDA-MB-231 and other invasive breast cancer cells will influence the course of tumor 
progression and metastatic process in vivo. Such experiments would be necessary in order to 
draw further conclusions about the role and significance of Foxp4 loss in breast cancer.       
 
3.4 Paper IV 
The Coxsackie- and Adenovirus Receptor Controls Akt Signaling and EMT in Breast 
Cancer Cells by Regulating Pten Localization and Stability at Tight Junctions  
Study II and III both indicate that loss of transcription factors that normally promote 
epithelial differentiation is important for the induction of EMT. In this study we wanted to 
determine whether changes in tight junctions, which are closely linked to and essential for 
epithelial differentiation, play a role in EMT. In particular we were interested in CAR, since it 
is an essential TJ in adult mice. We set out to test the hypothesis that CAR could be involved 
in regulating the TGF-β response. 
To test this hypothesis, we used EpRas and EpXT cells to perform gain and loss 
of function experiments. Knockdown of CAR in EpRas cells using siRNA did not affect 
expression of E-cadherin, Occludin and Vimentin after transfection, however with TGF-β1 
treatment further repression of both E-cadherin and occluding, and more induction of 
vimentin was induced in CAR knock down cells. In addition CAR knockdown lead to 
increased invasion towards a TGF-β1 gradient in the boyden chamber assay. Overexpression 
CAR in EpXT cells for 48h on the other hand, resulted in increased expression of both E-
cadherin and occludin, and decreased expression of Vimentin. EpXT cells overexpressing 
CAR were also less invasive compared to control cells. These data confirmed the hypothesis 
that CAR could regulate the EMT response in breast cancer cells. 
As previously discussed tight junction act as a hub for intracellular signals, and 
this lead us on to study if CAR knock down could change known signaling pathways 
downstream of the TGF-β receptor. Western blot analysis on CAR knockdown versus control 
cells indicated that phosphorylation of Smad3 (pSmad3), p38 (p-p38) and ERK1/2 (p-
ERK1/2) did not change neither at baseline nor after TGF-β1 treatment for 1 h. On the other 
hand, phosphorylation of Akt (p-Akt) was more prominent in CAR knockdown cells than 
control cells, both at baseline and after TGF-β1 treatment. Further, phosphorylation of Akt 
downstream target GSK-3β was increased in CAR knockdown cells, and immunoflourescent 
staining of knock down cells indicated increased levels of nuclear Snail and Twist1. These 
results suggest that the branch of Akt signaling inducing EMT is activated in cells with 
impaired CAR expression. 
Our next aim was to determine how CAR regulates Akt signaling in the cells. 
Interestingly, the phosphatase Pten, has been described to partially localize to tight junctions, 
and it is together with PI3K the major regulator of akt signaling. Pten localization to the TJs 
is mediated by interactions with the pdz-binding motif in the scaffolding proteins of MAGI 
protein family. One of the MAGI proteins, namely MAGI1, is also describe to interact with 
CAR, an interaction that is important for the recruitment and stabilization of MAGI1 to the 
TJs. 230,231 Based on these notions we aimed to investigate if CAR could stabilize Pten at TJs, 
something that would suppress Akt signaling. Immunoflourescence analysis on mammary 
EpH4 cells, with the capacity to polarize, revealed that both Pten and CAR co-locilezed at the 
TJs together with Magi1. Supporting physical interactions between these three proteins, co-
immunoprecipitation (Co-IP) experiments, using a MAGI1 antibody, precipitated both CAR 
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and Pten in EpH4 cells. Since CAR is lost gradually at TJs during TGF-b1 induced EMT we 
were interested to study if a similar pattern would be seen with Pten and Magi1. Indeed when 
we induced EMT for 48h in EpRas cells we found that all three proteins were mainly lost at 
TJs and that only a dot-like staining remained. Neither could Pten be detected at the TJs in 
EpXT cells which are stably in EMT. Further siRNA mediated knock down of CAR resulted 
in increased phosphorylation of Pten, which is known to cause destabilization of the protein, 
and lower total protein levels of Pten. Conversely overexpression of CAR lead to less 
phosphorylation of Pten and increased total protein levels. These data indicate a role of CAR 
in stabilization of Pten at the TJs. Based on this, we finally treated CAR knock down cells 
with a PITenin, a PIP3 antagonist, to verify if Akt activation in CAR knock down cells is 
bound to the activity of PIP3 conversion by Pten. Inhibition of PIP3 in CAR knock down 
cells partially reversed the Akt activation in siCAR expressing EpRas cells.        
  This study indicates that cell differentiation goes beyond transcriptional 
regulation and that the other parts of the epithelial phenotype, in this case CAR expression, 
play a part in maintaining the epithelial phenotype during EMT. As previously discussed, 
there are hubs were the TGF-β pathway is connected with other signaling pathways, but the 
multi molecular perspective on signaling is still far from understood. The data presented in 
this study suggest that TJs might be one of these hubs, acting to suppress TGF-β signaling.    
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4    CONCLUSION 
 
As we are rapidly increasing our knowledge of how tumors grow, turn invasive, and 
eventually metastasize to distant organs, we understand new levels of complexity from a 
molecular to multicellular level, and we are exploring many new ways to treat cancer 
patients, beyond the initial way to target uncontrolled cell growth. Our first study implies that 
this exploration might be fruitful, as inhibition of HKII, involved in metabolism, lead to re-
sensitization of cisplatin treatment and less proliferation of SKOV-3-R cells. In addition to 
this successful attempt, we also study the changeable features of SKOV-3-R cells, and found 
them to display EMT and CSC characteristics. Something we observed, but were unable to 
utilize as treatments. 
 Although this study aim to find alternative ways of treating ovarian cancer, it is 
obvious from our study, that we are repeatedly going back to evaluate the (same old) cancer 
hallmark of uncontrolled cell growth and proliferation. Perhaps, as we are evaluating new 
therapeutics based on profoundly different molecular and cell-functional backgrounds, we 
also need to reinvent the design of our studies on drugs, and have courage to expand the 
variety of readouts not only concerning tumor cell growth. Successful treatment targeting 
transition may not at all concern cell growth, but still prove valuable for clinical outcome in 
patients. The limitations in design of this study might also indicate that we currently know 
too little about cell transition in general and in particular lack ideas of how to apply it to 
cancer therapies.  
 In the following studies of this thesis we made an attempt to penetrate the topics 
of cell conversion and EMT, to elucidate molecular mechanisms behind TGF-β driven breast 
cancer progression and invasion. Our reasoning behind all these three studies were that 
transition of tumor cells, from epithelial to mesenchymal-like, is made possible when factors 
maintaining the initial epithelial phenotype are lost. In study II and III we investigate the role 
of the two transcription factors C/EBPβ and Foxp4, and in study IV the TJ and virus receptor 
CAR. All our studies pointed towards a role of these factors in determining breast cancer 
cells response to TGF-β.  
In the C/EBPβ study we found that loss of C/EBPβ during EMT through miR-
155 resulted in reduced expression of E-Cadherin and CAR. Interestingly, it is also known 
that Smad and LAP2 together induce G1 arrest through transcriptional activation of 
p15INK4b upon TGF-β1 treatment, suggesting, together with our results, that the processes 
of cell growth and transition are linked together. In study III, Foxp4 was shown to, as a 
transcriptional repressor of Snail1, have the capacity to inhibit TGF-β induced EMT. In 
addition, this study indicates that oncogenic RAS signaling might trigger loss of Foxp4 in 
breast tumors, again showing a connection between cell growth and EMT. Regarding 
transcriptional regulation, these two studies together with many others on transcriptional 
EMT regulators, reveal that transcription programs involving repressors and activators are 
needed to maintain phenotypes and that alterations due to stimuli such as TGF-β can 
potentiate changes in cells morphology and functionality, causing EMT. 
At a larger scale these studies hint towards the fact that molecules are versatile 
and shared between signaling pathways, used in different cellular processes, and linked 
together. In study IV we also find that CAR, previously thought of as a downstream target of 
TGF-β1 induced EMT and functionally promoting cell adhesion, to have an extended role in 
cell signaling. In fact, CAR serves to maintain Pten functionality at TJs, thus regulating Akt 
signaling which is highly coupled to EMT, but also cell growth, and other cellular processes. 
In the three last studies we did not characterize breast cancer cells, but aimed to study EMT, 
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in a hypothesis driven manner. Interestingly this has led us to a point where we, to some 
degree, understand the basis of cellular transition, not as a separate ontology or category of 
cellular processes, but in a bigger context being integrated with many. 
Based on this understanding, it might be possible that the transitory capacity of 
tumors can be used to e.g. reactivate growth inhibitory or apoptotic responses to currently 
used drugs, as a potential therapy for cancer. We might also attempt to use the changeable 
behavior to our advantage, by influencing the cellular fate of tumor cells. Potentially, this 
could be achieved through reactivation of factors similar to those being presented study II-IV, 
pushing cancer cells towards an epithelial cell fate, and preventing EMT. On the other hand, 
we know that many factors, both intracellular and extracellular, are involved in the induction 
of EMT, and that transition, in opposite to cell death, is not a terminal stage. Thus, it might 
prove difficult to first of all prevent EMT in cancer, and secondly to maintain suppression 
over a suspended period of time.  
Potential differentiation therapies might therefore profoundly differ from 
traditional chemotherapy, where treatments cannot rapidly break processes e.g. to induce cell 
death, but instead needs to work together with existing genetic programs in the cancer cells to 
achieve beneficial outcomes such as less invasion and EMT. Although EMT of tumor cells 
towards an invasive stage is well integrated with most (by today) defined hallmarks of cancer, 
it seems nevertheless plausible that great therapeutic benefits from work on cellular transition 
and differentiation, will occur only if we go beyond these hallmarks and even the cancerous 
disease itself. Perhaps, work in accordance with genetic programs in a therapeutic purpose 
will prove to be lifelong treatments.  
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